Disease/Infection News

RSS

New WHO report shows considerable progress in malaria

According to the World Health organization’s World Malaria Report 2009 released earlier this week, more than one third of affected countries included in the study have witnessed reduction in malaria cases by more than 50 percent between 2000 and 2008.

18 Dec 2009

Bill & Melinda Gates Foundation grants funds for visceral leishmaniasis research

The Hebrew University of Jerusalem Kuvin Center for the Study of Infectious and Tropical Diseases has received a $5 million grant from the Bill & Melinda Gates Foundation for research into visceral leishmaniasis.

18 Dec 2009

Genetic variant associated with reduced risk of COPD

What: Researchers have discovered evidence that suggests a genetic variant may be associated with better preserved lung function among children with asthma and adults who smoke, according to a new study funded by the National Heart, Lung, and Blood Institute (NHLBI), which is part of the National Institutes of Health.

18 Dec 2009

Flu-fighting proteins found in human cells stop flu virus, uncover scientists

In findings that may lead to better ways to prevent and treat influenza and other viral infections, researchers report the discovery of a family of naturally occurring antiviral agents in human cells.

18 Dec 2009

Comprehensive approaches to understand the interaction of H1N1 strains with human cells

Scientists have generated hundreds of new leads in the fight against the H1N1 flu pandemic, according to two new studies published online December 17th in the journal Cell, a Cell Press publication.

18 Dec 2009

Hebrew University of Jerusalem receives $5 million grant from Bill & Melinda Gates Foundation

17 Dec 2009

Update on Phase 2 clinical trial of oral interferon announced by Amarillo Biosciences

Amarillo Biosciences, Inc. (ABI) today announced that its ongoing study of oral interferon as prevention/treatment of influenza and other respiratory illnesses in Perth, Australia is nearing completion.

17 Dec 2009

La Jolla Institute for Allergy & Immunology awarded $18.8M NIH grant for infectious diseases study

Researchers from the La Jolla Institute for Allergy & Immunology will take aim at several of the world's most dangerous infectious diseases - tuberculosis, malaria and dengue virus -- in a five-year, $18.8 million federally-funded set of projects seeking to make new inroads toward vaccines against the disorders.

17 Dec 2009

PEPFAR decisions to be grounded in scientific evidence, Goosby says

U.S. Global AIDS Coordinator Eric Goosby "said future programmes to prevent HIV infection would be those supported by the best scientific evidence," reports the Financial Times. Goosby told the Financial Times in an interview: "I will always wrap myself in the science as the justification of decision-making. I will not factor in an ideological rationale."

17 Dec 2009

African AIDS vaccine conference addresses future trials in Africa, lower participation rates among women

During the Forum of the African AIDS Vaccine Program (AAVP) in Kampala, Uganda, on Wednesday, Alan Bernstein, the director of the Global HIV Vaccine Enterprise, discussed ongoing efforts to launch an experimental HIV vaccine trial - similar to the recent trial in Thailand - in Africa, the Daily Monitor reports.

17 Dec 2009

Hebrew University of Jerusalem granted $5M for research into visceral leishmaniasis in Ethiopia

17 Dec 2009

EPA approves BASF's Aseptrol S10 - Tab for H1N1 sanitization operations

BASF today announced that the Environmental Protection Agency (EPA) has approved the use of Aseptrol® S10 - Tab in H1N1 sanitization operations in institutional and industrial facilities, such as, schools, hospitals, government buildings, retail and restaurants, and recreational facilities. Aseptrol S10 - Tab is based on Chlorine dioxide (CIO2) release technology.

17 Dec 2009

AlphaRx, Venturepharm sign supply agreement for ARX1088's API

AlphaRx Inc. announced today that it has signed an agreement that provides long-term supply of the active pharmaceutical ingredient (API) for ARX1088, an orally active interferon inducer intended for the adjunctive treatment of Hepatitis in China and other emerging markets. Under the agreement, Venturepharm will be the primary supplier of AlphaRx's worldwide requirements for the compound.

17 Dec 2009

Anadys Pharmaceuticals reports positive 4-week results from its ANA598 Phase II study for HCV

Anadys Pharmaceuticals, Inc. today announced preliminary results from a planned interim analysis of data at four weeks for the first dose cohort, 200 mg bid, in an ongoing Phase II study of ANA598 in combination with pegylated interferon and ribavirin (SOC) in HCV patients.

17 Dec 2009

Three H1N1 influenza vaccination clinics scheduled to offer vaccines free of charge

2010 is just over two weeks away. Make a New Year's resolution for you and your family members and start the new year out right by getting your H1N1 influenza shot at one of the available clinics in southeast Michigan.

17 Dec 2009

MIT to host community-wide Caregiver Kit Build Event

Boston AIDS Africa, a Boston-based initiative to respond to the AIDS pandemic in Africa by providing vital supplies to care for those suffering with HIV/AIDS in Africa, announced today that it has partnered with Massachusetts Institute of Technology (MIT) in Cambridge, who will host a community-wide Caregiver Kit Build Event on April 3, 2010 at the MIT Johnson Ice Rink.

17 Dec 2009

Risk of H1N1 exposure alters U.S. holiday plans

Forty percent of U.S. adults intend to change their holiday plans due to the risk of being exposed to the H1N1 flu virus, according to a nationwide survey commissioned by JohnsonDiversey, a global leader in the commercial cleaning and sanitizing industry.

17 Dec 2009

Disease/Infection News

New WHO report shows considerable progress in malaria

Bill & Melinda Gates Foundation grants funds for visceral leishmaniasis research

Genetic variant associated with reduced risk of COPD

Flu-fighting proteins found in human cells stop flu virus, uncover scientists

Comprehensive approaches to understand the interaction of H1N1 strains with human cells

Hebrew University of Jerusalem receives $5 million grant from Bill & Melinda Gates Foundation

Update on Phase 2 clinical trial of oral interferon announced by Amarillo Biosciences

La Jolla Institute for Allergy & Immunology awarded $18.8M NIH grant for infectious diseases study

PEPFAR decisions to be grounded in scientific evidence, Goosby says

African AIDS vaccine conference addresses future trials in Africa, lower participation rates among women

Hebrew University of Jerusalem granted $5M for research into visceral leishmaniasis in Ethiopia

EPA approves BASF's Aseptrol S10 - Tab for H1N1 sanitization operations

AlphaRx, Venturepharm sign supply agreement for ARX1088's API

Anadys Pharmaceuticals reports positive 4-week results from its ANA598 Phase II study for HCV

Three H1N1 influenza vaccination clinics scheduled to offer vaccines free of charge

MIT to host community-wide Caregiver Kit Build Event

Risk of H1N1 exposure alters U.S. holiday plans

Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial

Cannabis for Ulcerative Colitis and Crohn's Disease treatment

Scientists analyze more than 21 million calls to determine the spread of malaria

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News